January 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable electronic injector designed to enhance the administration of injectable medications while helping partners meet their sustainability goals.
Cambridge, MA. - January 7, 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable injector designed to enhance the administration of injectable medications. Built on Portal’s robust platform technology, the PRIME Nexus is a needle-based device designed to be compatible with standard primary containers, including 1mL pre-filled syringes (PFS), 2.25mL PFS, and 3mL cartridges.
The PRIME Nexus represents a significant advancement in drug delivery, offering precise control and versatility for a wide range of therapies. This innovative device is poised to be a game-changer for pharmaceutical companies and patients alike, offering several key advantages:
The PRIME Nexus is designed to seamlessly integrate into existing manufacturing and packaging processes, streamlining the development and commercialization of new injectable therapies. Its compatibility with standard primary containers further simplifies integration and reduces development timelines.
Portal Instruments will showcase the PRIME Nexus device at Pharmapack and other key industry events. Attendees will have the opportunity to see the device in action and discuss feasibility or development studies for this reusable injector.
About Portal Instruments:
Portal Instruments is a privately held medical device company focused on developing and commercializing innovative drug delivery platform technologies to transform the administration of injectable medications. Portal's goal is to improve patient experience, adherence, and outcomes by providing advanced delivery solutions.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
November 21, 2023 - Patrick Anquetil, CEO of Portal Instruments, takes the stage at LSI's 2023 Emerging MedTech Summit in Dana Point, California. Tune in to the recorded session to hear Dr. Anquetil dive into the innovative world of of needle-free and Portal's groundbreaking needle-free technology.
February 2020 - Portal Instruments was pleased to welcome Ali Ward and team from CBS’s Innovation Nation to show them Portal’s needle-free injector. The Henry Ford’s Innovation Nation is “a weekly Saturday morning show on CBS that showcases present-day change-makers from all over the world.
Please fill out the details below and we will get back to you shortly.